ArticleInternational journal of chronic obstructive pulmonary disease2026
Risk Factors and Prediction of Chronic Obstructive Pulmonary Disease After Pulmonary Tuberculosis: A Prospective Cohort Study.
Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary tuberculosis (PTB) is increasingly recognized as a major precursor of chronic obstructive pulmonary disease (COPD). However, validated tools to predict the risk of COPD following PTB cure remain limited. Early identification of individuals at high risk is essential to facilitate targeted follow-up and preventive interventions. Methods: This prospective cohort study was conducted at Hunan Chest Hospital. Adults with newly diagnosed PTB who completed standard anti-tuberculosis treatment were enrolled between January and June 2023 and followed until June 2025. Follow-up assessments were performed monthly during the first 3 months, quarterly from months 6 to 12, and every 6 months thereafter, with standardized evaluation of respiratory symptoms and lung function. Incident COPD was defined as a post-bronchodilator FEV Results: During follow-up, 83 of 324 participants (25.6%) developed COPD. Older age (≥65 years), active smoking, cavitary PTB, invasive fungal disease, dyspnea, an elevated systemic immune-inflammation index (SII), and a reduced CD4⁺/CD8⁺ T-cell ratio were independently associated with COPD development. A prediction model incorporating these seven variables demonstrated good discrimination, with an area under the receiver operating characteristic curve of 0.806 (95% CI: 0.751-0.861), and satisfactory calibration. Internal validation yielded a bootstrap-corrected concordance index of 0.787, indicating favorable clinical utility across a broad range of decision thresholds. Conclusion: More than one-quarter of patients developed COPD after PTB cure, highlighting the substantial burden of post-tuberculosis respiratory sequelae. The proposed prediction model enables individualized risk stratification and may support early surveillance and targeted preventive strategies, extending post-TB care beyond microbiological cure to long-term respiratory outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.